secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-10-21T23:59:59+00:00
Accession:  0000950170-24-115767
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene announces executive changes: new CTO, CSO, and President; Sullivan separation
--------------------------------------------------------------------------------

- Joan Connolly appointed CTO effective Oct 21; brings 30+ yrs experience from Albireo, Stemline, Bristol-Myers.
- Anthony Cheung transitions from CTO to CSO; James Sullivan departs Oct 31, 2024.
- Sullivan separation agreement includes $485k salary continuation, prorated bonus, equity acceleration, option extension.
- Alexander Nichols becomes Chief Strategy & Operations Officer; CEO Ron Cooper adds President title.
- Detalimogene pivotal study ongoing; enGene expects BLA submission mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/0000950170-24-115767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024115767/engn-20241016.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-115767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer